Ventus Medical Appoints John McCutcheon as President and CEO.- - Also Announces the expansion of PROVENT(R) Sleep Apnea sleep apnea, episodes of interrupted breathing during sleep. Obstructive sleep apnea is a common disorder in which relaxation of muscles in the throat repeatedly close off the airway during sleep; the person wakes just enough to take a gasping breath. Therapy in Limited US Markets
BELMONT, Calif., April 9 /PRNewswire/ -- Ventus Medical, Inc. a privately-held, medical device company, focused on transforming the Sleep Disordered Breathing market, today announced the appointment of John McCutcheon as President and Chief Executive Officer, effective April 20, 2009. The company also announced that current CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Jeffrey Nugent will become Executive Chairman.
Mr. McCutcheon joins Ventus Medical from Emphasys Medical where he was President and CEO for the past seven years. Previously, he was head of Sales and Marketing at Perclose, an Abbott Laboratories company and in senior marketing positions at Devices for Vascular Intervention and Baxter Healthcare.
"John is the ideal leader to drive the commercialization of PROVENT Therapy as a novel treatment of obstructive sleep apnea (OSA 1. OSA - Open Scripting Architecture.
2. OSA - Open System Architecture. ). He is a proven leader in the medical device field with nearly 25 years of experience," said Mr. Nugent. "Clinical studies have shown that PROVENT Therapy has the potential to improve the quality of life for millions of people around the world who suffer from this disorder," he added. "We are encouraged by the acceptance we are experiencing at both the physician and patient level at the sleep centers where PROVENT Therapy is currently available."
PROVENT Therapy has been cleared by the Food and Drug Administration and is indicated for the treatment of obstructive sleep apnea. PROVENT Therapy is a daily use, prescription device and works across mild, moderate, and severe OSA.
"I am pleased to join Ventus Medical at this exciting time in the Company's development," said John McCutcheon. "PROVENT Therapy is one of the most innovative products to be introduced into the sleep apnea market in years: it is a convenient, discreet dis·creet
1. Marked by, exercising, or showing prudence and wise self-restraint in speech and behavior; circumspect.
2. Free from ostentation or pretension; modest. and portable solution. We look forward to working closely with the medical community to meet the need for more patient-friendly, effective sleep apnea treatments."
PROVENT Therapy is currently available in a limited number of markets and is in the process of expanding with the assistance and support of professional sleep physicians in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. .
Also, Ventus Medical has just been awarded the 2009 Medical Design Excellence Award which recognizes those companies responsible for the ground breaking innovations that are changing the face of healthcare.
Ventus Medical's investors include De Novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. Ventures, Mohr Davidow Ventures and the Johnson & Johnson Development Corporation. Information on Ventus Medical and PROVENT Therapy can be found on http://www.ventusmedical.com/ and http://www.proventtherapy.com/.
CONTACT: Greg Johnstone, VP of Finance of Ventus Medical, Inc., +1-650-632-4170, email@example.com
Web Site: http://www.ventusmedical.com/ http://www.proventtherapy.com/